174 related articles for article (PubMed ID: 26102535)
1. Low tetanus, diphtheria and acellular pertussis (Tdap) vaccination coverage among HIV infected individuals in Austria.
Grabmeier-Pfistershammer K; Herkner H; Touzeau-Roemer V; Rieger A; Burgmann H; Poeppl W
Vaccine; 2015 Jul; 33(32):3929-32. PubMed ID: 26102535
[TBL] [Abstract][Full Text] [Related]
2. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
[TBL] [Abstract][Full Text] [Related]
3. Immune response to a Tdap booster in vertically HIV-infected adolescents.
Spina FG; Gouvea A; Succi RCM; Calanca F; Weckx LY; Terreri MT; Takano MAS; de Moraes-Pinto MI
Vaccine; 2018 Sep; 36(37):5609-5616. PubMed ID: 30087050
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
5. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
Dominicus R; Galtier F; Richard P; Baudin M
Vaccine; 2014 Jun; 32(31):3942-9. PubMed ID: 24852717
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
8. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
[TBL] [Abstract][Full Text] [Related]
11. Meningococcal Conjugate and Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccination Among HIV-infected Youth.
Setse RW; Siberry GK; Moss WJ; Wheeling J; Bohannon BA; Dominguez KL;
Pediatr Infect Dis J; 2016 May; 35(5):e152-7. PubMed ID: 26855409
[TBL] [Abstract][Full Text] [Related]
12. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).
Murphy TV; Slade BA; Broder KR; Kretsinger K; Tiwari T; Joyce PM; Iskander JK; Brown K; Moran JS;
MMWR Recomm Rep; 2008 May; 57(RR-4):1-51. PubMed ID: 18509304
[TBL] [Abstract][Full Text] [Related]
13. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults.
Scott LJ
BioDrugs; 2010 Dec; 24(6):387-406. PubMed ID: 21043546
[TBL] [Abstract][Full Text] [Related]
14. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine.
Tomovici A; Barreto L; Zickler P; Meekison W; Noya F; Voloshen T; Lavigne P
Vaccine; 2012 Mar; 30(16):2647-53. PubMed ID: 22353673
[TBL] [Abstract][Full Text] [Related]
15. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
16. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
Weston W; Messier M; Friedland LR; Wu X; Howe B
Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
[TBL] [Abstract][Full Text] [Related]
17. Waning Tdap Effectiveness in Adolescents.
Klein NP; Bartlett J; Fireman B; Baxter R
Pediatrics; 2016 Mar; 137(3):e20153326. PubMed ID: 26908667
[TBL] [Abstract][Full Text] [Related]
18. Low seroprevalence of diphtheria, tetanus and pertussis in ambulatory adult patients: the need for lifelong vaccination.
Tanriover MD; Soyler C; Ascioglu S; Cankurtaran M; Unal S
Eur J Intern Med; 2014 Jul; 25(6):528-32. PubMed ID: 24814432
[TBL] [Abstract][Full Text] [Related]
19. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
[TBL] [Abstract][Full Text] [Related]
20. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
Gidengil CA; Sandora TJ; Lee GM
Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
